These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 17208672)
41. Effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% administered in the evening in glaucoma. Polo V; Larrosa JM; Ferreras A; Borque E; Pablo LE; Honrubia FM Ann Ophthalmol (Skokie); 2008; 40(3-4):157-62. PubMed ID: 19230353 [TBL] [Abstract][Full Text] [Related]
42. Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range. Varma R; Hwang LJ; Grunden JW; Bean GW; Sultan MB Am J Ophthalmol; 2009 Aug; 148(2):221-6. PubMed ID: 19427617 [TBL] [Abstract][Full Text] [Related]
43. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111 [TBL] [Abstract][Full Text] [Related]
44. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741 [TBL] [Abstract][Full Text] [Related]
45. Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis. Nowroozzadeh MH Am J Ophthalmol; 2009 Apr; 147(4):754; author reply 754-5. PubMed ID: 19327446 [No Abstract] [Full Text] [Related]
46. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407 [TBL] [Abstract][Full Text] [Related]
47. Discrepancy of the intraocular pressure response between fellow eyes in one-eye trials versus bilateral treatment: verification with normal subjects. Takahashi M; Higashide T; Sakurai M; Sugiyama K J Glaucoma; 2008; 17(3):169-74. PubMed ID: 18414100 [TBL] [Abstract][Full Text] [Related]
48. Daily cost of ophthalmic solutions used to treat allergic conjunctivitis in Japan. Ikeda H; Tsukamoto H; Sato E; Mishima HK; Kihira K Ophthalmic Epidemiol; 2004 Feb; 11(1):35-42. PubMed ID: 14977495 [TBL] [Abstract][Full Text] [Related]
49. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Sakurai M; Higashide T; Takahashi M; Sugiyama K Ophthalmology; 2007 Jun; 114(6):1039-45. PubMed ID: 17467803 [TBL] [Abstract][Full Text] [Related]
50. Determinants of eye drop size. Van Santvliet L; Ludwig A Surv Ophthalmol; 2004; 49(2):197-213. PubMed ID: 14998692 [TBL] [Abstract][Full Text] [Related]
51. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406 [TBL] [Abstract][Full Text] [Related]
52. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302 [TBL] [Abstract][Full Text] [Related]
53. Contact dermatitis caused by latanoprost-containing eye drops with good tolerance to bimatoprost eye drops. Pérez-Rodríguez E; González-Pérez R; Poza P; Feliciano L; López-Correcher B; Matheu V Contact Dermatitis; 2008 Jun; 58(6):370-1. PubMed ID: 18503690 [No Abstract] [Full Text] [Related]
54. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Bournias TE; Lai J Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma. Kumar RS; Istiantoro VW; Hoh ST; Ho CL; Oen FT; Aung T J Glaucoma; 2007; 16(7):606-9. PubMed ID: 18091178 [TBL] [Abstract][Full Text] [Related]
56. Squeeze Me if You Can: Variability in Force Requirements to Extract a Drop From Common Glaucoma Bottles. Moore DB; Hammer JD; Akhtari R; Beck J; Sanders S; Kryscio RJ J Glaucoma; 2016 Sep; 25(9):780-4. PubMed ID: 27552516 [TBL] [Abstract][Full Text] [Related]
57. Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptor. St Peter DM; Steger JS; Patnaik JL; Davis N; Kahook MY; Seibold LK Med Devices (Auckl); 2023; 16():71-79. PubMed ID: 37056302 [TBL] [Abstract][Full Text] [Related]
58. Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies. Velpandian T; Kotnala A; Halder N; Ravi AK; Archunan V; Sihota R Curr Eye Res; 2015 May; 40(6):561-71. PubMed ID: 25494824 [TBL] [Abstract][Full Text] [Related]
59. A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study. Eaton AM; Gordon GM; Konowal A; Allen A; Allen M; Sgarlata A; Gao G; Wafapoor H; Avery RL Eye (Lond); 2015 Oct; 29(10):1383-91. PubMed ID: 26358235 [TBL] [Abstract][Full Text] [Related]
60. Innovative bulls eye drop applicator for self-instillation of eye drops. Taneja M; Chappidi K; Harsha Ch SNS; Richhariya A; Mohamed A; Rathi VM Cont Lens Anterior Eye; 2020 Jun; 43(3):256-260. PubMed ID: 31813766 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]